IL‐10 vs placebo
Withdrawls due to adverse events · induction of remission in Crohn's disease
IL‐10 probably leads to higher withdrawls due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Recombinant human interleukin 10 for induction of remission in Crohn's disease 2010 · Cochrane Headline outcomes onlyRR 13.5 [3.89, 46.79]2 studies · 228 participantsModerate